Severity of Brugada syndrome disease manifestation and risk of new-onset depression or anxiety: a Danish nationwide study

Abstract Aims Reduced psychological health is associated with adverse patient outcomes and higher mortality. We aimed to examine if a Brugada syndrome (BrS) diagnosis and symptomatic disease presentation were associated with an increased risk of new-onset depression or anxiety and all-cause mortality. Methods and results All Danish patients diagnosed with BrS (2006–2018) with no history of psychiatric disease and available for ≥6 months follow-up were identified using nationwide registries and followed for up to 5 years after diagnosis. The development of clinical depression or anxiety was evaluated using the prescription of medication and diagnosis codes. Factors associated with developing new-onset depression or anxiety were determined using a multivariate Cox proportional hazards regression model. Disease manifestation was categorized as symptomatic (aborted cardiac arrest, ventricular tachycardia, or syncope) or asymptomatic/unspecified at diagnosis. A total of 223 patients with BrS and no history of psychiatric disease were identified (72.6% male, median age at diagnosis 46 years, 45.3% symptomatic). Of these, 15.7% (35/223) developed new-onset depression or anxiety after BrS diagnosis (median follow-up 5.0 years). A greater proportion of symptomatic patients developed new-onset depression or anxiety compared with asymptomatic patients [21/101 (20.8%) and 14/122 (11.5%), respectively, P = 0.08]. Symptomatic disease presentation (HR 3.43, 1.46–8.05) and older age (lower vs. upper tertile: HR 4.41, 1.42–13.63) were significantly associated with new-onset depression or anxiety. All-cause mortality in this group of patients treated according to guidelines was low (n = 4, 1.8%); however, 3/4 developed depression or anxiety before death. Conclusion Approximately, one-sixth of patients with BrS developed new-onset depression or anxiety following a diagnosis of BrS. Symptomatic BrS disease manifestation was significantly associated with new-onset depression or anxiety.

[1]  L. Køber,et al.  Use of Nonrecommended Drugs in Patients With Brugada Syndrome: A Danish Nationwide Cohort Study , 2023, Journal of the American Heart Association.

[2]  T. Friede,et al.  European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death , 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  P. Lambiase,et al.  2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. , 2022, European heart journal.

[4]  L. Køber,et al.  Workforce attachment after a congenital long QT syndrome diagnosis: a Danish nationwide study , 2022, Open Heart.

[5]  Jørgen K. Kanters,et al.  Severity of congenital long QT syndrome disease manifestation and risk of depression, anxiety, and mortality: a nationwide study. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  C. James,et al.  Anxiety and depression in inherited channelopathy patients with implantable cardioverter-defibrillators , 2021, Heart rhythm O2.

[7]  K. McGeechan,et al.  A prospective longitudinal study of health-related quality of life and psychological wellbeing after an implantable cardioverter-defibrillator in patients with genetic heart diseases , 2021, medRxiv.

[8]  G. Parati,et al.  Brugada syndrome and syncope: a practical approach for diagnosis and treatment. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  S. Möller,et al.  Anxiety and depression symptoms in Danish patients with an implantable cardioverter-defibrillator: prevalence and association with indication and sex up to 2 years of follow-up (data from the national DEFIB-WOMEN study). , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  J. Skinner,et al.  How Patient Perceptions Shape Responses and Outcomes in Inherited Cardiac Conditions. , 2019, Heart, lung & circulation.

[11]  H. Bundgaard,et al.  Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality. , 2019, European heart journal.

[12]  T. Potpara,et al.  Patients’ knowledge and attitudes regarding living with implantable electronic devices: results of a multicentre, multinational patient survey conducted by the European Heart Rhythm Association , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[13]  H. Calkins,et al.  Quality of life metrics in arrhythmogenic right ventricular cardiomyopathy patients: The impact of age, shock and sex. , 2017, International journal of cardiology.

[14]  J. Brugada,et al.  Clinical outcome of patients with the Brugada type 1 electrocardiogram without prophylactic implantable cardioverter defibrillator in primary prevention: a cumulative analysis of seven large prospective studies , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[15]  J. Skinner,et al.  Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome , 2017, Journal of the American College of Cardiology.

[16]  B. Penninx,et al.  Increased mortality among people with anxiety disorders: total population study , 2016, British Journal of Psychiatry.

[17]  M. Hintsanen,et al.  Stressful life events and depressive symptoms among symptomatic long QT syndrome patients , 2016, Journal of health psychology.

[18]  T. Laursen,et al.  Mortality and life expectancy in persons with severe unipolar depression. , 2016, Journal of affective disorders.

[19]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[20]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[21]  C. Semsarian,et al.  Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. , 2013, International journal of cardiology.

[22]  P. Weeke,et al.  Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[23]  A. Wilde,et al.  Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[24]  Jørgen K. Kanters,et al.  Low disease prevalence and inappropriate implantable cardioverter defibrillator shock rate in Brugada syndrome: a nationwide study. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  Emily A. Kuhl,et al.  The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. , 2011, Journal of psychosomatic research.

[26]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[27]  F. Sacher,et al.  The psychological impact of implantable cardioverter defibrillator implantation on Brugada syndrome patients. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[28]  Carolyn M. Reilly,et al.  Effect of a Psychoeducational Intervention on Depression, Anxiety, and Health Resource Use in Implantable Cardioverter Defibrillator Patients , 2009, Pacing and clinical electrophysiology : PACE.

[29]  S. Priori,et al.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). , 2009, Heart rhythm.

[30]  E. Behr,et al.  Drug-induced Brugada syndrome. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[31]  Florence Thibaut,et al.  A comparison of anxiety, depression and quality of life between device shock and nonshock groups in implantable cardioverter defibrillator recipients. , 2009, General hospital psychiatry.

[32]  S. Puttonen,et al.  Depressive symptoms in the congenital long QT syndrome , 2009, Annals of medicine.

[33]  M. Hendriks,et al.  Familial disease with a risk of sudden death: a longitudinal study of the psychological consequences of predictive testing for long QT syndrome. , 2008, Heart rhythm.

[34]  M. Whooley,et al.  Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. , 2005, Archives of internal medicine.

[35]  J. Davidson,et al.  Nonpharmacologic Treatments for Depression in Patients With Coronary Heart Disease , 2005, Psychosomatic medicine.

[36]  OUP accepted manuscript , 2022, European Heart Journal - Quality of Care and Clinical Outcomes.

[37]  J. Bostwick,et al.  An updated review of implantable cardioverter/defibrillators, induced anxiety, and quality of life. , 2011, Heart failure clinics.